Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.43% | -62.22% | -69.92% | 11.36% | -44.34% |
| Total Depreciation and Amortization | -0.34% | -2.38% | -1.67% | -1.10% | -6.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -79.14% | 56.22% | -1.52% | -57.71% | 17.31% |
| Change in Net Operating Assets | -183.67% | -791.00% | 49.11% | -97.79% | 78.30% |
| Cash from Operations | -32.95% | -148.25% | -46.32% | -39.35% | -9.37% |
| Capital Expenditure | 18.93% | -64.82% | -917.67% | -295.58% | -157.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 176.09% | 13.22% | 35.00% | -232.51% | -7,784.09% |
| Cash from Investing | 175.83% | 12.88% | 34.34% | -234.00% | -8,201.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 9.53% | 55.05% | 117.88% | 409.19% | 179.86% |
| Issuance of Common Stock | -99.99% | -94.96% | -94.28% | 416.18% | 850.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 898.37% | 4,544.52% | 4,544.52% | 4,544.52% | 227.38% |
| Cash from Financing | -99.09% | -94.21% | -93.58% | 351.89% | 701.88% |
| Foreign Exchange rate Adjustments | 855.61% | 244.11% | 383.97% | 759.58% | 111.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -71.30% | -188.98% | -184.69% | 1,701.54% | 132.52% |